Sewon Cellontech Obtains Japanese Patent for Technology Enhancing Bio-Collagen Preservation and Extraction Efficiency

[Asia Economy Reporter Hyungsoo Park] Sewon Cellontech announced on the 13th that it has completed patent registration in Japan for its collagen production technology for medical (biomaterial) use, which improves preservation and extraction efficiency.

A Sewon Cellontech official introduced it as "a patent related to a method that simultaneously improves the quality and extraction efficiency of collagen by irradiating radiation at the initial stage of collagen manufacturing to sterilize animal-derived tissues."

Based on the optimization and aseptic process of Sewon Cellontech's Regenerative Medical System Innovation Center, the company explained that it can enhance the preservation of collagen and maximize extraction efficiency without denaturation.

Seo Dongsam, head of Sewon Cellontech's Regenerative Medical System Innovation Center, emphasized, "Sterilization and yield improvement are efficiently achieved simultaneously by a single manufacturing process, which has high industrial utilization value," and added, "it is significant to secure patent rights in Japan, where the medical collagen field and collagen-based technologies are well established."

Previously, Sewon Cellontech commercialized the medical collagen brand ‘BioCollagen’ based on various foundational technologies. BioCollagen is a raw pharmaceutical material registered with the U.S. Food and Drug Administration (FDA) that possesses biocompatibility, safety, and tissue regeneration capabilities. It is characterized by maintaining the inherent properties and structure of collagen present in the body.

Sewon Cellontech plans to respond to the increasing demand for BioCollagen based on the RMS CAMP under construction in the Geumgok General Industrial Complex in Namyangju-si, Gyeonggi-do.

This content was produced with the assistance of AI translation services.